Rak predstatel'noy zhelezy: vozmozhnosti primeneniya agonistov lyuteiniziruyushchego gormona - rilizing-gormona
- Authors: Shakhnovich E.B1, Kopyl'tsov A.A1, Sultanova N.O1, Kerbikov O.B1
-
Affiliations:
- Issue: No 18 (2014)
- Pages: 71-74
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287506
- ID: 287506
Cite item
Open Access
Access granted
Abstract
In most countries of the world, increased morbidity and mortality from prostate cancer (PCa) are observed. This article discusses the epidemiology, main methods for diagnosis of prostate cancer, and options for its hormonal treatment. The most common type of hormonal therapy for PCa, promoting tumor regression, includes the use of luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists, as the most appropriate drugs for the medical castration, can be used as monotherapy for the local, locally advanced and metastatic prostate cancer, and as a component of maximal androgen blockade in combination with anti-androgens.
Full Text
References
- ECD/European Union. «Cancer Incidence», in Health at a Glance: Europe 2010. OECD Publishing, 2010
- Злокачественные новообразования в России в 2012 году (заболеваемость и смертность) / Под редакцией А.Д. Каприна, В.В. Старинского, .В. Петровой. М., 2014.
- Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 2004;350(22): 2239-46.
- Sharifi N, Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-44.
- Huggins C., Stevens R.E. Jr, Hodges C.V. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941;43:209-23.
- Oefelein M.G., Feng A., Scolieri M.J., et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urologyy. 2000;56(6):1021-24.
- Kaisary A.V., Tyrrell C.J., Peeling W.B., Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate carcinoma. Br. J. Urol. 1991;67:502-8.
- Матвеев Б.П., Матвеев В.Б., Бухаркин Б.В. Аналоги (агонисты) ЛГРГ. В кн.: Рак предстательной железы. М., 1999. С. 126-41.
- PCTCG. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trails. Lancet. 2002;355:1491-98.
- Seiden feld J., Samson D.J., Hasselblad V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 2000;132(7):566-77.
- Бухаркин Б.В. Современная медикаментозная гормональная терапия первично выявленного диссеминированного рака предстательной железы. Русский медицинский журнал. 2003;11:688-90.
- Соков Д.Г., Русаков И.Г. Влияние агонистов лютеинизирующего гормона рилизинг-гормона на уровень тестостерона и качество жизни у больных местнораспространенным и генерализованным раком предстательной железы. Российский онкологический журнал. 2011;1:33-6.
Supplementary files
